|
The DAPT Study: The Dual Antiplatelet Therapy (DAPT) Study
Summary
The aim of this study is to conduct a multicenter, international, randomized, double-blind trial to help the global medical community to better assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects without contraindications following percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions.
Description
Winthrop-University Hospital - Division of Cardiology is conducting this clinical research trial for participants, greater than 18 years of age and who have undergone percutaneous intervention with stent deployment. All enrolled subjects will be treated according to the standard of practice for the thienopyridine treatment in addition to aspirin for first 12 months after the index procedure. Eligible subjects will be randomized 1:1 at 12 months to receive placebo or thienopyridine treatment for an additional 18 months. Subjects will be followed for an additional 3 months for observational follow-up at the end of the 18 month randomized treatment phase.
Inclusion/exclusion
To be eligible for this clinical trial, you must: - Be older than 18 years - Must have undergone percutaneous intervention with stent deployment.
Principal Investigator
Srihari Naidu, MD
Department
Division of Cardiology
Email
ssnaidu@winthrop.org
Other Contact
For more information please call Research Coordinator at 516-663-8692.
|
